Drug intelligence / Profile preview

Coricidin HBP

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

**Coricidin HBP** is a brand line of over-the-counter combination medications designed for cold and flu symptom relief, particularly safe for individuals with high blood pressure as it contains no decongestants. Different formulations include **Coricidin HBP Cough & Cold** (chlorpheniramine maleate 4 mg as antihistamine + dextromethorphan hydrobromide 30 mg as cough suppressant), **Coricidin HBP Maximum Strength Multi-Symptom Flu** (acetaminophen 325-500 mg as pain reliever/fever reducer + chlorpheniramine maleate 2 mg + dextromethorphan HBr 10-15 mg), and others like Chest Congestion (dextromethorphan + guaifenesin). These act via analgesia (acetaminophen inhibits prostaglandin synthesis), H1 receptor antagonism (chlorpheniramine blocks histamine to reduce rhinorrhea/sneezing), antitussive suppression of cough reflex (dextromethorphan acts on sigma-1 receptors in the medulla), and expectoration (guaifenesin increases respiratory secretions). Originally introduced by Schering-Plough in 1949, now manufactured by Bayer HealthCare LLC, it provides temporary relief for cough, congestion, pain, fever, and runny nose in adults/children ≥12 years, taken orally every 4-6 hours with liver warnings due to acetaminophen.[1][2][4][5][7][8][11]

Brand names
Coricidin HBP
Other names
Coricidin HBP Cough & ColdCoricidin HBP Maximum Strength Multi-Symptom FluCoricidin HBP Cold and Flu
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Coricidin HBP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coricidin HBP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call